The wasting continuum in heart failure: from sarcopenia to cachexia
Open Access
- 12 August 2015
- journal article
- review article
- Published by Cambridge University Press (CUP) in Proceedings of the Nutrition Society
- Vol. 74 (4), 367-377
- https://doi.org/10.1017/s0029665115002438
Abstract
Sarcopenia (muscle wasting) and cachexia share some pathophysiological aspects. Sarcopenia affects approximately 20 %, cachexia <10 % of ambulatory patients with heart failure (HF). Whilst sarcopenia means loss of skeletal muscle mass and strength that predominantly affects postural rather than non-postural muscles, cachexia means loss of muscle and fat tissue that leads to weight loss. The wasting continuum in HF implies that skeletal muscle is lost earlier than fat tissue and may lead from sarcopenia to cachexia. Both tissues require conservation, and therapies that stop the wasting process have tremendous therapeutic appeal. The present paper reviews the pathophysiology of muscle and fat wasting in HF and discusses potential treatments, including exercise training, appetite stimulants, essential amino acids, growth hormone, testosterone, electrical muscle stimulation, ghrelin and its analogues, ghrelin receptor agonists and myostatin antibodies.Keywords
This publication has 104 references indexed in Scilit:
- Cachexia as a major public health problem: frequent, costly, and deadlyJournal of Cachexia, Sarcopenia and Muscle, 2013
- Development and relative validity of a new field instrument for detection of geriatric cachexia: preliminary analysis in hip fracture patientsJournal of Cachexia, Sarcopenia and Muscle, 2013
- Development of a practical screening tool to predict low muscle mass using NHANES 1999–2004Journal of Cachexia, Sarcopenia and Muscle, 2013
- Low appendicular skeletal muscle mass (ASM) with limited mobility and poor health outcomes in middle‐aged African AmericansJournal of Cachexia, Sarcopenia and Muscle, 2013
- Effect of ghrelin and its analogues, BIM‐28131 and BIM‐28125, on the expression of myostatin in a rat heart failure modelJournal of Cachexia, Sarcopenia and Muscle, 2012
- The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer:Journal of Cachexia, Sarcopenia and Muscle, 2011
- Myopenia—a new universal term for muscle wastingJournal of Cachexia, Sarcopenia and Muscle, 2011
- An overview of sarcopenia: facts and numbers on prevalence and clinical impactJournal of Cachexia, Sarcopenia and Muscle, 2010
- The effects of a high‐caloric protein‐rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double‐blind pilot studyJournal of Cachexia, Sarcopenia and Muscle, 2010
- Efficacy and Safety of Exercise Training in Patients With Chronic Heart FailureJAMA, 2009